Hercules Capital Inc Share Price Nyse
Equities
US4270968880
Investment Management & Fund Operators
End-of-day quote
Other stock markets
|
||
- USD | - |
17/05 | UBS Adjusts Price Target on Hercules Capital to $18.50 From $18, Maintains Neutral Rating | MT |
15/05 | Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital | MT |
Sales 2024 * | 509M 42.42B | Sales 2025 * | 553M 46.02B | Capitalization | 3.1B 258B |
---|---|---|---|---|---|
Net income 2024 * | 341M 28.39B | Net income 2025 * | 345M 28.73B | EV / Sales 2024 * | 6.08 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.6 x |
P/E ratio 2024 * |
9.17
x | P/E ratio 2025 * |
9.51
x | Employees | - |
Yield 2024 * |
8.5% | Yield 2025 * |
8.54% | Free-Float | 98.08% |
Latest transcript on Hercules Capital Inc
Managers | Title | Age | Since |
---|---|---|---|
Scott Bluestein
CEO | Chief Executive Officer | 45 | 17/10/17 |
Seth H. Meyer
DFI | Director of Finance/CFO | 55 | 04/19/04 |
Kiersten Botelho
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gayle Crowell
BRD | Director/Board Member | 73 | 04/19/04 |
Robert Badavas
CHM | Chairman | 71 | 01/06/01 |
Director/Board Member | 61 | 26/23/26 |
1st Jan change | Capi. | |
---|---|---|
+12.82% | 1.77B | |
+9.42% | 1.52B | |
-11.54% | 1.2B | |
+16.35% | 771M | |
+10.17% | 671M | |
+31.22% | 562M | |
-4.17% | 505M | |
+27.48% | 472M | |
+73.57% | 321M |